Alexandra Gerlach, Associate Editor

Approximately 10% of patients with multiple myeloma have pathogenic germline variants, indicating a hereditary risk.

Use of dexamethasone over tocilizumab was associated with significant cost-savings for patients with relapsed/refractory multiple myeloma (RRMM).

Vepdegestrant is an experimental oral PROteolysis TArgeting Chimera that degrades estrogen receptor (ER) in patients with metastatic breast cancer.

The favorable outcomes were observed in the phase 3 AMPLIFY trial.

The outbreak has grown to a total of 222 confirmed cases of measles, as well as 2 measles-associated deaths.

A pilot program integrated oncology pharmacists into prior authorization workflows to streamline and expedite medication approvals.

Subcutaneous infusion reduces treatment times for patients and eases operational burdens for providers.

Policymakers and health care providers call for reforms to improve transparency, pricing, and patient access.

Specialty pharmacists are critical for enhanced management of clinical and logistical aspects of treatment.

Camizestrant is an investigational oral selective estrogen receptor degrader.

The authors’ findings show a greater decline in those treated with chemotherapy vs endocrine therapy.

The data supports quadruplet therapy’s potential in the first line for patients with newly diagnosed multiple myeloma (NDMM).

The decision is based on clinically meaningful results from a phase 3 trial.

The decisions were made amid the United States worst flu outbreak in over 2 decades.

The data were released in the CDC’s Morbidity and Mortality Weekly Report.

Trastuzumab rezetecan is a novel antibody-drug conjugate.

The advanced therapy yielded superior enhanced mucus secretion compared with available therapies.

Patients achieved an overall survival of 12.4 months.

Glecirasib is a potent oral inhibitor of KRASG12C.

Sacituzumab govitecan improves outcomes but requires careful management of adverse effects.

Officials urge vaccinations as mobile vaccine drives ramp up to contain the outbreak.

Fred Saad, MD, discussed findings from the phase 3 ARANOTE and ARASENS trials.

Risk stratification remains a challenge when selecting patients for treatment of smoldering multiple myeloma.

Clinical pharmacists can optimize treatment through effective medication management and therapeutic drug monitoring.

Pembrolizumab is a humanized monoclonal antibody that targets PD-1.

Tanshinlactone is an active ingredient that is commonly used in Chinese herbal medicine.

The test results are available in as little as 20 minutes.

In a study of 5 different drugs, amlodipine was the only one to reduce hyperactivity in patients with attention-deficit hyperactivity disorder (ADHD).

The approach targets cancer glucose and fatty acid metabolism, which is essential for cancer cell growth.

Treatment with semaglutide yielded superior effects on drinking outcomes compared with existing therapies to reduce alcohol cravings.